TABLE OF CONTENT: 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1. Prevalence of Psoriatic Arthritis for Key Countries/Region 4.2. Recent Industry Developments Such as Partnerships, Mergers & Acquisitions, New Product Launches Etc. 4.3. Pipeline Analysis for Key Companies 4.4. Regulatory Framework by Key Countries 4.5. Global Reimbursement Scenario 5. Global Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2015-2026 5.1. Key Findings / Summary 5.2. Market Analysis, Insights and Forecast – By Drug Class 5.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 5.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs 5.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs 5.3. Market Analysis, Insights and Forecast – By Route of Administration 5.3.1. Oral 5.3.2. Parenteral 5.3.3. Topical 5.4. Market Analysis, Insights and Forecast – By Distribution Channel 5.4.1. Hospital Pharmacies 5.4.2. Retail Pharmacies 5.4.3. Online Pharmacies 5.5. Market Analysis, Insights and Forecast – By Region 5.5.1. North America 5.5.2. Europe 5.5.3. Asia pacific 5.5.4. Latin America 5.5.5. Middle East & Africa 6. North America Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2015-2026 6.1. Key Findings / Summary 6.2. Market Analysis – By Drug Class 6.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 6.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs 6.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs 6.3. Market Analysis – By Route of Administration 6.3.1. Oral 6.3.2. Parenteral 6.3.3. Topical 6.4. Market Analysis – By Distribution Channel 6.4.1. Hospital Pharmacies 6.4.2. Retail Pharmacies 6.4.3. Online pharmacies 6.5. Market Analysis – By Country 6.5.1. U.S. 6.5.2. Canada 7. Europe Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2015-2026 7.1. Key Findings / Summary 7.2. Market Analysis – By Drug Class 7.2.1. Non-steroidal Anti-inflammatory Drugs 7.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs 7.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs 7.3. Market Analysis – By Route of Administration 7.3.1. Oral 7.3.2. Parenteral 7.3.3. Topical 7.4. Market Analysis – By Distribution Channel 7.4.1. Hospital Pharmacies 7.4.2. Retail Pharmacies 7.4.3. Online pharmacies 7.5. Market Analysis – By Country/Sub-region 7.5.1. U.K. 7.5.2. Germany 7.5.3. France 7.5.4. Spain 7.5.5. Italy 7.5.6. Scandinavia 7.5.7. Rest of Europe 8. Asia Pacific Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2015-2026 8.1. Key Findings / Summary 8.2. Market Analysis – By Drug Class 8.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 8.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs 8.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs 8.3. Market Analysis – By Route of Administration 8.3.1. Oral 8.3.2. Parenteral 8.3.3. Topical 8.4. Market Analysis – By Distribution Channel 8.4.1. Hospital Pharmacies 8.4.2. Retail Pharmacies 8.4.3. Online pharmacies 8.5. Market Analysis – By Country/Sub-region 8.5.1. Japan 8.5.2. China 8.5.3. India 8.5.4. Australia 8.5.5. Southeast Asia 8.5.6. Rest of Asia Pacific 9. Latin America Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2015-2026 9.1. Key Findings / Summary 9.2. Market Analysis – By Drug Class 9.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 9.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs 9.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs 9.3. Market Analysis – By Route of Administration 9.3.1. Oral 9.3.2. Parenteral 9.3.3. Topical 9.4. Market Analysis – By Distribution Channel 9.4.1. Hospital Pharmacies 9.4.2. Retail Pharmacies 9.4.3. Online pharmacies 9.5. Market Analysis – By Country/Sub-region 9.5.1. Brazil 9.5.2. Mexico 9.5.3. Rest of Latin America 10. Middle East & Africa Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2015-2026 10.1. Key Findings / Summary 10.2. Market Analysis – By Drug Class 10.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 10.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) 10.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs 10.3. Market Analysis – By Route of Administration 10.3.1. Oral 10.3.2. Parenteral 10.3.3. Topical 10.4. Market Analysis – By Distribution Channel 10.4.1. Hospital Pharmacies 10.4.2. Retail Pharmacies 10.4.3. Online pharmacies 10.5. Market Analysis – By Country/Sub-region 10.5.1. GCC Countries 10.5.2. South Africa 10.5.3. Rest of Middle East & Africa 11. Competitive Analysis 11.1. Key Industry Developments 11.2. Global Market Share Analysis (2018) 11.3. Competition Dashboard 11.4. Comparative Analysis – Major Players 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability)) 11.5.1. AbbVie Inc. 11.5.2. Novartis AG 11.5.3. Johnson & Johnson Services, Inc. 11.5.4. Pfizer Inc., 11.5.5. LEO Pharma A/S 11.5.6. Merck & Co., Inc. 11.5.7. Amgen Inc. 11.5.8. Eli Lilly and Company 11.5.9. CELGENE CORPORATION 11.5.10. UCB S.A. 11.5.11. Sun Pharmaceutical Industries Ltd. 11.5.12. Other prominent players 12. Strategic Recommendation

AbbVie Inc. Novartis AG Johnson & Johnson Services, Inc. Pfizer Inc., LEO Pharma A/S Merck & Co., Inc. Amgen Inc. Eli Lilly and Company CELGENE CORPORATION UCB S.A. Sun Pharmaceutical Industries Ltd. Other prominent players